Roivant Sciences LTD Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Roivant Sciences Ltd. reported changes in beneficial ownership of Roivant Sciences Ltd. common stock on October 1, 2026.
NASDAQ
Melissa B Epperly, a Director of Roivant Sciences Ltd., sold 17,750 shares of common stock on October 1, 2026.
NASDAQ
Matthew Gline, CEO and a Director of Roivant Sciences Ltd., reported a transaction in 76,171 shares of common stock on September 30, 2026.
NASDAQ
Frank Torti, President and Vant Chair of Roivant Sciences Ltd., reported a transaction in 40,309 shares of common stock on September 30, 2026.
NASDAQ
Mayukh Sukhatme, President & CIO and a Director of Roivant Sciences Ltd., reported a transaction in 46,879 shares of common stock on September 30, 2026.
NASDAQ
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 shares of common stock on September 30, 2026 for $36.62 per share.
NASDAQ
Jennifer Humes, Chief Accounting Officer of Roivant Sciences Ltd., reported a transaction in 3,880 shares of common stock on September 20, 2026.
NASDAQ
Richard Pulik, CFO of Roivant Sciences Ltd., reported a transaction in 2,129 shares of common stock on September 20, 2026.
NASDAQ
Keith S Manchester, a Director of Roivant Sciences Ltd., reported multiple transactions in common stock on September 16, 2026.
NASDAQ
Daniel Allen Gold, a Director of Roivant Sciences Ltd., reported multiple transactions in common stock on September 16, 2026.
NASDAQ
Ilan Oren, a Director of Roivant Sciences Ltd., reported multiple transactions in common stock on September 16, 2026.
NASDAQ
James C Momtazee, a Director of Roivant Sciences Ltd., reported multiple transactions in common stock on September 16, 2026.
NASDAQ
Meghan Fitzgerald, a Director of Roivant Sciences Ltd., reported multiple transactions in common stock on September 16, 2026.
NASDAQ
Melissa B Epperly, a Director of Roivant Sciences Ltd., reported multiple transactions in common stock on September 16, 2026.
NASDAQ
Melissa B Epperly, a Director of Roivant Sciences Ltd., sold 4,938 shares of common stock on September 15, 2026.
NASDAQ
Meghan Fitzgerald, a Director of Roivant Sciences Ltd., sold 5,112 shares of common stock on September 15, 2026.
NASDAQ
Daniel Allen Gold, a Director of Roivant Sciences Ltd., reported a transaction in 5,133 shares of common stock on September 10, 2026.
NASDAQ
Ilan Oren, a Director of Roivant Sciences Ltd., reported a transaction in 2,378 shares of common stock on September 10, 2026.
NASDAQ
Melissa B Epperly, a Director of Roivant Sciences Ltd., reported a transaction in 2,179 shares of common stock on September 10, 2026.
NASDAQ
Meghan Fitzgerald, a Director of Roivant Sciences Ltd., reported a transaction in 1,743 shares of common stock on September 10, 2026.
NASDAQ
James C Momtazee, a Director of Roivant Sciences Ltd., reported a transaction in 2,905 shares of common stock on September 10, 2026.
NASDAQ
Meghan Fitzgerald, a Director of Roivant Sciences Ltd., sold 20,000 shares of common stock on September 8, 2026 for $39.90 per share.
NASDAQ
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 shares of common stock on August 28, 2026.
NASDAQ
Richard Pulik, CFO of Roivant Sciences Ltd., reported a transaction in 5,749 shares of common stock on August 20, 2026.
NASDAQ
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., reported a transaction in 13,909 shares of common stock on August 20, 2026.
NASDAQ
Mayukh Sukhatme, President & CIO and a Director of Roivant Sciences Ltd., sold 335,174 shares of common stock on August 19, 2026.
NASDAQ
Mayukh Sukhatme, President & CIO and a Director of Roivant Sciences Ltd., sold 664,826 shares of common stock on August 14, 2026.
NASDAQ
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 shares of common stock on July 27, 2026 for $34.95 per share.
NASDAQ
James C Momtazee, a Director of Roivant Sciences Ltd., received 405 shares of common stock on July 17, 2026.
NASDAQ
Melissa B Epperly, a Director of Roivant Sciences Ltd., received 543 shares of common stock on July 17, 2026.